Cayman E2012

GUDCA is a glycine-conjugated form of the secondary bile acid ursodeoxycholic acid (UDCA; Item No. ).^, It has antioxidant effects in vitro in Barrett’s esophagus cells and primary cultured rat neurons.^, GUDCA reduces the levels of inflammatory cytokines and prevents cell death induced by unconjugated bilirubin (Item No. ) in an astroglial cell model of neonatal hyperbilirubinemia. Oral administration of GUDCA (500 mg/kg per day) decreases the severity of symptoms and increases the amount of A. muciniphila, a commensal bacterial species commonly decreased in patients with inflammatory bowel disease (IBD), in a mouse model of colitis.

Glycoursodeoxycholic Acid MaxSpec^® Standard standard is a quantitative grade standard of glycoursodeoxycholic acid (Item No. ) that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This Glycoursodeoxycholic Acid MaxSpec^® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.

WARNING This product is not for human or veterinary use.